FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda Pharmaceuticals opposes FDA proposal to extend drug review timelines
-
-
-
-
-
-
-
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
-
-
-
-
-
-
-
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Reiterated at Outperform by Cantor Fitzgerald
-
-
-
-
-
-
-
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
-
-
-
-
-
-
-
Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, random
-
326,426 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

